About
Technology
Issues
FAQ
Links
Official Page
CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.